OptiNose, Inc. (OPTN) Hits All-Time High

June 29, 2018 - By Maria Fierro

OptiNose, Inc. (NASDAQ:OPTN) touched $28.26 price per share on Jun, 29, also an all time high. This chart pattern was announced by Barchart.com. OptiNose, Inc. (NASDAQ:OPTN) has $1.15 billion MC. The valuation of NASDAQ:OPTN can change by $57.65M if our $29.67 price target is touched.

OPTN reached $28.26 during the last trading session after $0.2 change.OptiNose, Inc. has volume of 46,133 shares. Since June 29, 2017 OPTN has 0.00% and is . OPTN underperformed by 12.57% the S&P 500.

OptiNose, Inc. (NASDAQ:OPTN)’s quarterly earnings will be reported on August, 13., as reported by Faxor. -2.47 % EPS growth is what analysts predict. $-0.81 earnings per share was reported for previous quarter.

For more OptiNose, Inc. (NASDAQ:OPTN) news published briefly go to: Globenewswire.com, Globenewswire.com, Streetinsider.com, Nasdaq.com or Streetinsider.com. The titles are as follows: “Optinose Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional …” published on June 11, 2018, “Optinose Announces Pricing of Public Offering of Common Stock” on June 07, 2018, “OptiNose (OPTN) Prices 5 Million Common Shares at $22.25 Per Share” with a publish date: June 07, 2018, “Optinose CEO Peter Miller and President and COO Ramy Mahmoud Named EY Life Sciences Entrepreneur Of The …” and the last “OptiNose (OPTN) Commences 4.5M Share Offering of Common Stock” with publication date: June 04, 2018.

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States.The firm is valued at $1.15 billion. The firm offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.Currently it has negative earnings. It also markets Onzetra Xsail for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.